ReviewWiener klinische Wochenschrift2026
[Sex and gender-specific aspects in prediabetes and diabetes mellitus - Clinical recommendations (Update 2026)].
Review in Wiener klinische Wochenschrift, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the clinical routine treating physicians are confronted with the different needs of women and men, which change during their lifetime. Gender-specific differences influence the pathophysiology, screening, diagnostic and treatment strategies of diabetes as well as the development of complications and mortality rates. Alterations in glucose and lipid metabolism, regulation of energy balance and body fat distribution as well as diabetes-associated comorbidities, are greatly influenced by steroidal and sex hormones as well as by lifestyle, environmental factors, income and psychosocial factors. Males appear to have a greater risk for type 2 diabetes (T2DM) at a younger age and at a lower body mass index (BMI) compared to women but women show a higher BMI and more often hypertension at diagnosis and are affected by a dramatic increase in the risk for cardiometabolic diseases after the menopause. The estimated future years of life lost owing to diabetes is somewhat higher in women than men, whereby the higher mortality is mainly attributable to vascular complications. The increased mortality due to cancer in men with diabetes seems to bear more weight than by women. Both sexes benefit from prevention programs with a reduction in the risk for T2DM. Men predominantly feature increased fasting blood glucose levels, women often show impaired glucose tolerance. A history of gestational diabetes or increased androgen levels in women and the presence of erectile dysfunction or decreased testosterone levels in men are important sex-specific diabetes risk factors. Many studies showed that women with diabetes reach their target values for glycated hemoglobin (HbA1c), blood pressure and low-density lipoprotein (LDL)-cholesterol less often than men. Sex differences in the effects, pharmacokinetics and side effects of pharmacological treatment should be taken more into consideration with better achievement of individual target levels in men and women.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.